Investor Ideas #Potcasts
563, #Cannabis News and #Stocks on the Move; (CSE: $XTRX.C), (TSXV: $KHRN.V)
(OTCQX: $KHRNF), (CSE: $CURA.C) (OTCQX: $CURLF), (CSE: $DELC.C) (OTCQB: $DELCF),
(OTC: $MJNA)
Delta, Kelowna, BC, May 11, 2021 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/051121-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2021/cannabis-potcasts/05111XTRX-KHRN-CURA-DELC-MJNA.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
Today’s
podcast is sponsored by Phyto
Extractions Inc. (CSE:XTRX), an
agricultural-scale cannabis extraction, distillation and product manufacturer
located in Langley, BC at its co-located Health Canada Licensed Standard
Processing (extraction, no cultivation), Sales (extracts, topicals, and
edibles) through Adastra Labs Inc. and Analytical Testing Laboratory through
Chemia Analytics Inc. Adastra Labs also has a pending Health Canada R&D
license amendment.
In
today’s podcast we look at a few public company announcements.
Khiron
Life Sciences Corp. (TSXV:
KHRN) (OTCQX:
KHRNF), a vertically integrated cannabis leader with core
operations in Latin America and Europe,
applauds the publication today in the accredited scientific journal
"Psychopharmacology" of the first findings arising from Project
Twenty 21, UK's first and largest national medical cannabis registry that was
launched on November 7, 2019 at the Royal College of Psychiatrists in London.
Through Project Twenty21, eligible
patients can access affordable medical cannabis treatment, monitored by Drug
Science, UK's leading independent scientific body. The project aims to create
the UK's largest body of evidence for the effectiveness and tolerability of
medical cannabis to warrant NHS funding where the benefits of treatment with
medical cannabis are proven to outweigh the potential risks.
The Project Twenty 21 study has now
licensed prescriptions of medical cannabis to over 900 patients who are in
substantially poorer health than the general population, and who have been
unable to manage their diagnosed conditions with commonly prescribed
medicines. The findings show that
legally prescribed cannabis provides clinically significant improvements in the
quality of life of patients living with conditions such as Chronic Pain,
Multiple Sclerosis, Tourette's Syndrome, Epilepsy and Post Traumatic Stress
Disorder (PTSD). Based on the early positive momentum of the Project Twety21,
Khiron will be launching other commercial initiatives to reach as many people
as possible in the country.
The patient data collected show that
medical cannabis improves the quality of life more than classical treatments
do, for example for neuropathic pain. According to the National Institute for
Clinical Excellence (NICE), there is little or no evidence that commonly
prescribed drugs, such as benzodiazepines or opioids, make any difference to
people's quality of life, pain or psychological distress, but they can cause
harm, including possible addiction. In contrast, the results of Project
Twenty21 clearly show a fifty percent increase in patients' self-reported
health and ability to lead a more normal life as well as significant
improvements in patients' ability to manage debilitating secondary conditions
such as anxiety, insomnia and depression. Also, patients are now able to avoid
criminality with legal prescriptions, as many have felt compelled to turn to
illegal use to manage their conditions.
Project leader of Twenty21 Professor
David Nutt from Drug Science, comments: "A lack of clinical evidence has
made it difficult for doctors to confidently prescribe legal medical cannabis
in the UK. These new findings provide a major step forward and help to clarify
the benefit these medicines can have for thousands of seriously ill
patients."
Tejinder Virk, President of Khiron
Europe, says: "We are glad to see our strong commitment with medical
research bear its fruits with this publication. Khiron is a true pioneer in the
medical cannabis landscape in the UK, and not just because of its products. Our
biggest contribution to improve access to medical cannabis in the UK is our education
programs for prescribing clinicians and the dissemination of our expertise with
cannabis-based therapeutics. We plan to continue our data-driven approach with
the deployment of EU-GMP cannabinoid-based medicines based on our Colombian
extracts, whose efficacy and safety are backed by clinical data collected in
our wholly-owned clinics with over 17,000 prescriptions."
Curaleaf Holdings,
Inc. (CSE:
CURA) (OTCQX:
CURLF), a leading international provider of consumer
products in cannabis, today
announced that wholly owned Curaleaf International subsidiary
Adven GmbH ("Adven") has launched its own range of medical cannabis
products in Germany, Europe's largest medical cannabis market. The initial launch of a high THC oil product
aims to meet immediate patient demand and will be extended over the course of
the year to incorporate a number of different strengths and THC/CBD
formulations in both oil and flower formats, addressing a wide range of patient
needs. Germany is Europe's largest medical cannabis market and is expected to
be worth US$2.1 billion by 2025.
Antonio
Costanzo, CEO of Curaleaf International, said, "We are very pleased to
bring our first medical cannabis products to market in Germany and, with the
rapid extension of our product range in 2021, establishing ourselves as a
leader in Europe's largest medical cannabis market. Curaleaf International's
European supply chain, from cultivation to product research and development and
EU-GMP manufacturing processes across Europe, means we are able to guarantee a
consistency of product and price to clinicians and patients in need of the
highest quality medical cannabis."
Julian
Vaterrodt, Managing Director, Adven GmbH, added, "German patients and practitioners are increasingly demanding
high-quality, consistent and reliable European natural alternatives to help
manage a wide range of complaints. Adven
is committed to providing a differentiated product and service for the German
market. We focus on providing a consistent supply of high-quality European
medical cannabis and cutting-edge digital technologies to improve the patient
and healthcare professional experience."
Delic Holdings Inc. (CSE:
DELC) (OTCQB:
DELCF) a psychedelic wellness platform, announced that
its acquisition target (under binding letter agreement see news release dated
February 4, 2021), Ketamine Infusion Centers ("KIC"), proposes to acquire
two (2) additional licensed ketamine clinics in Arizona. The proposed
acquisition would double the footprint of the infusion chain and become the
largest operator in the state of Arizona.
"This
is a major step toward becoming the largest ketamine clinic operator in the
country, bringing superior quality and expanding access for patients,"
said Matt Stang, Delic CEO and co-founder. "KIC is the leading name in
high quality care and incredible outcomes for its patients and this move helps
grow that reputation significantly. As a vital part of the Delic platform, KIC
will continue to offer wellness and benefits for many people suffering from
anxiety, depression and PTSD."
Over
the past three years, the team at KIC has expanded from Arizona to California, while
overseeing 4,000 treatments administered to date, and generating more than
$1.5-million (U.S.) in revenue. KIC continues to operate under the Delic
umbrella, under the direction and guidance of Dr. Christopher Ray, Sonny Diaz,
Rogelio Monzon and Ganesh Acharya. With the successful completion of the
acquisition, KIC will expand to 3 clinics in Arizona, with locations in Central
Phoenix, East Valley, and West Valley, and 1 in California, with a location in
Bakersfield.
Sonny
Diaz, co-founder of KIC, stated: "We are thrilled to join the Delic family
and double our footprint with this acquisition, allowing greater access to
patients for these vital services. Ketamine Infusion Centers unique model and
passion to obtain the highest patient outcomes and purely evidence-based
practices is a perfect fit in the Delic ecosystem. Together with their vast
knowledge of psychedelic wellness, strong partner channels and mission to bring
psychedelic wellness into the mainstream, we see unlimited potential of how
many lives we may positively affect together."
As
part of these two sublease transactions, KIC will assume ownership of both
licences, which contain the OTC licenses for the respective locations at no
additional costs. KIC will submit the necessary paperwork to the State of
Arizona to complete the license transfer processes.
Medical Marijuana,
Inc. (OTC:
MJNA), the first-ever publicly traded cannabis company in
the United States that launched the world’s first-ever cannabis-derived
nutraceutical products, brands and supply chain, announced
today that its subsidiary HempMeds® Brasil had its best
revenue month ever in Company history in April 2021.
“Our
HempMeds Brasil operations have seen a consistent increase over the years. We
aim to reach as many consumers in need as possible and last month’s
achievements prove that we are continuing to expand our reach to our target
audiences,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus.
“I
am incredibly proud of the success our HempMeds Brasil team has been able to
achieve. As we celebrate our best revenue month in company history, we are
scaling our operations in the country, refreshing our consumer-facing website and
increasing the size of our facilities in Brazil to meet the needs of our
expanding team,” said HempMeds® CEO Raul Elizalde.
“In
the coming months, to support our continued growth, we intend to partner with
the largest higher education institution in Brazil to educate medical
professionals on the potential benefits of cannabidiol (CBD) and are moving
forward in securing partnerships with well-respected professional and Olympic
athletes,” said HempMeds® Brasil Managing Director Matheus Patelli. “My team has
successfully been able to show Brazilian citizens that our products are of the
highest quality and trustworthy, just like the people who work at the Company.”
Once
again, today’s podcast is sponsored by Phyto
Extractions Inc. (CSE:XTRX), an
agricultural-scale cannabis extraction, distillation and product manufacturer
located in Langley, BC at its co-located Health Canada Licensed Standard
Processing (extraction, no cultivation), Sales (extracts, topicals, and
edibles) through Adastra Labs Inc. and Analytical Testing Laboratory through
Chemia Analytics Inc. Adastra Labs also has a pending Health Canada R&D
license amendment.
Investor
ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and that this podcast is not an endorsement to buy
products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment.
Learn
more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To
hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The
Investorideas.com podcasts are also available on iTunes ( Apple Podcasts)
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio , Google Play
Music and most audio platforms available.
Potcasts
is now a certified word mark Trademark on the blockchain through Cognate, Inc.
CM Certification-Registration Number: 10468217708
Investors can trade these stocks and other ideas on our site using our list of
top stock trading apps including
Robinhood , Acorn, Stash and others.
About
Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and
equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
No comments:
Post a Comment